{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T20:34:55Z","timestamp":1776544495774,"version":"3.51.2"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s00415-025-13242-6","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T22:37:50Z","timestamp":1753310270000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparing the efficacy and safety of cyclophosphamide, infliximab and methotrexate in neurosarcoidosis: a multicenter retrospective study"],"prefix":"10.1007","volume":"272","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-2761-843X","authenticated-orcid":false,"given":"H\u00e9l\u00e8ne","family":"Gomez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"No\u00ebl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Achille","family":"Aouba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertrand","family":"Bourre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Langlois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marine","family":"Avenel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ygal","family":"Benhamou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathilde","family":"Leclercq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"issue":"3","key":"13242_CR1","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.revmed.2023.01.013","volume":"44","author":"AC Desbois","year":"2023","unstructured":"Desbois AC, Shor N, Chapelon C, Maillart E, Touitou V, Cacoub P et al (2023) Atteinte neurologique de la sarco\u00efdose : strat\u00e9gies diagnostiques et th\u00e9rapeutiques actuelles. Rev Med Interne 44(3):123\u2013132","journal-title":"Rev Med Interne"},{"key":"13242_CR2","doi-asserted-by":"publisher","first-page":"970168","DOI":"10.3389\/fneur.2022.970168","volume":"13","author":"P Sambon","year":"2022","unstructured":"Sambon P, Sellimi A, Kozyreff A, Gheysens O, Pothen L, Yildiz H et al (2022) Epidemiology, clinical presentation, treatment, and outcome of neurosarcoidosis: a mono-centric retrospective study and literature review. Front Neurol. 13:970168","journal-title":"Front Neurol."},{"issue":"11","key":"13242_CR3","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1001\/jamaneurol.2017.2492","volume":"74","author":"B Joubert","year":"2017","unstructured":"Joubert B, Chapelon-Abric C, Biard L, Saadoun D, Demeret S, Dormont D et al (2017) Association of prognostic factors and immunosuppressive treatment with long-term outcomes in neurosarcoidosis. JAMA Neurol 74(11):1336\u20131344","journal-title":"JAMA Neurol"},{"issue":"20","key":"13242_CR4","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1212\/WNL.0000000000004644","volume":"89","author":"JM Gelfand","year":"2017","unstructured":"Gelfand JM, Bradshaw MJ, Stern BJ, Clifford DB, Wang Y, Cho TA et al (2017) Infliximab for the treatment of CNS sarcoidosis: a multi-institutional series. Neurology. 89(20):2092","journal-title":"Neurology."},{"issue":"5","key":"13242_CR5","doi-asserted-by":"publisher","first-page":"e847","DOI":"10.1212\/NXI.0000000000000847","volume":"7","author":"D Fritz","year":"2020","unstructured":"Fritz D, Timmermans WMC, van Laar JAM, van Hagen PM, Siepman TAM, van de Beek D et al (2020) Infliximab treatment in pathology-confirmed neurosarcoidosis. Neurol Neuroimmunol Neuroinflamm 7(5):e847","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"24","key":"13242_CR6","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1212\/WNL.0000000000003431","volume":"87","author":"S Bitoun","year":"2016","unstructured":"Bitoun S, Bouvry D, Borie R, Mahevas M, Sacre K, Haroche J et al (2016) Treatment of neurosarcoidosis: a comparative study of methotrexate and mycophenolate mofetil. Neurology. 87(24):2517\u20132521","journal-title":"Neurology."},{"issue":"12","key":"13242_CR7","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1001\/jamaneurol.2018.2295","volume":"75","author":"BJ Stern","year":"2018","unstructured":"Stern BJ, Royal W III, Gelfand JM, Clifford DB, Tavee J, Pawate S et al (2018) Definition and consensus diagnostic criteria for neurosarcoidosis: from the Neurosarcoidosis Consortium Consensus Group. JAMA Neurol. 75(12):1546\u201353","journal-title":"JAMA Neurol."},{"key":"13242_CR8","doi-asserted-by":"publisher","first-page":"A38","DOI":"10.1016\/j.revmed.2020.10.067","volume":"41","author":"W Bigot","year":"2020","unstructured":"Bigot W, Chapelon-Abric C, Mangin O, Champion K, Mouly S, Cacoub P et al (2020) \u00c9valuation du cyclophosphamide au cours de la neuro-sarco\u00efdose: \u00e9tude r\u00e9trospective chez 32 patients. La Revue de M\u00e9decine Interne. 41:A38","journal-title":"La Revue de M\u00e9decine Interne."},{"issue":"2","key":"13242_CR9","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1002\/acn3.51968","volume":"11","author":"S Chaiyanarm","year":"2023","unstructured":"Chaiyanarm S, Satiraphan P, Apiraksattaykul N, Jitprapaikulsan J, Owattanapanich W, Rungjirajittranon T et al (2023) Infliximab in neurosarcoidosis: a systematic review and meta-analysis. Ann Clin Trans Neurol. 11(2):466","journal-title":"Ann Clin Trans Neurol."},{"issue":"5","key":"13242_CR10","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s00415-017-8444-9","volume":"264","author":"F Cohen Aubart","year":"2017","unstructured":"Cohen Aubart F, Bouvry D, Galanaud D, Dehais C, Mathey G, Psimaras D et al (2017) Long-term outcomes of refractory neurosarcoidosis treated with infliximab. J Neurol 264(5):891\u2013897","journal-title":"J Neurol"},{"issue":"5","key":"13242_CR11","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1007\/s00415-019-09234-y","volume":"266","author":"Q Riller","year":"2019","unstructured":"Riller Q, Cotteret C, Junot H, Benameur N, Haroche J, Mathian A et al (2019) Infliximab biosimilar for treating neurosarcoidosis: tolerance and efficacy in a retrospective study including switch from the originator and initiation of treatment. J Neurol 266(5):1073\u20131078","journal-title":"J Neurol"},{"issue":"9","key":"13242_CR12","doi-asserted-by":"publisher","first-page":"e0238391","DOI":"10.1371\/journal.pone.0238391","volume":"15","author":"P Cacoub","year":"2020","unstructured":"Cacoub P, Chapelon-Abric C, Resche-Rigon M, Saadoun D, Desbois AC, Biard L (2020) Cardiac sarcoidosis: a long term follow up study. PLoS One. 15(9):e0238391","journal-title":"PLoS One."},{"issue":"10","key":"13242_CR13","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/j.amjcard.2019.07.067","volume":"124","author":"LJ Harper","year":"2019","unstructured":"Harper LJ, McCarthy M, Neto MLR, Hachamovitch R, Pearson K, Bonanno B et al (2019) Infliximab for refractory cardiac sarcoidosis. Am J Cardiol 124(10):1630\u20135","journal-title":"Am J Cardiol"},{"issue":"4","key":"13242_CR14","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s12350-022-03171-6","volume":"30","author":"R Vis","year":"2023","unstructured":"Vis R, Mathijssen H, Keijsers RGM, van de Garde EMW, Veltkamp M, Akdim F et al (2023) Prednisone vs methotrexate in treatment na\u00efve cardiac sarcoidosis. J Nucl Cardiol 30(4):1543\u20131553","journal-title":"J Nucl Cardiol"},{"issue":"18","key":"13242_CR15","doi-asserted-by":"publisher","first-page":"e010952","DOI":"10.1161\/JAHA.118.010952","volume":"8","author":"DG Rosenthal","year":"2019","unstructured":"Rosenthal DG, Parwani P, Murray TO, Petek BJ, Benn BS, de Marco T et al (2019) Long-term corticosteroid-sparing immunosuppression for cardiac sarcoidosis. J Am Heart Assoc. 8(18):e010952","journal-title":"J Am Heart Assoc."},{"issue":"4","key":"13242_CR16","doi-asserted-by":"publisher","first-page":"e743","DOI":"10.1212\/NXI.0000000000000743","volume":"7","author":"J Lord","year":"2020","unstructured":"Lord J, Paz Soldan MM, Galli J, Salzman KL, Kresser J, Bacharach R et al (2020) Neurosarcoidosis. Neurol Neuroimmunol Neuroinflamm. 7(4):e743","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"2","key":"13242_CR17","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.semarthrit.2017.03.005","volume":"47","author":"Y Jamilloux","year":"2017","unstructured":"Jamilloux Y, Cohen-Aubart F, Chapelon-Abric C, Maucort-Boulch D, Marquet A, P\u00e9rard L et al (2017) Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: a multicenter study of 132 patients. Semin Arthrit Rheum 47(2):288\u201394","journal-title":"Semin Arthrit Rheum"},{"issue":"1","key":"13242_CR18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/jcm8010015","volume":"8","author":"A Ibrahim","year":"2018","unstructured":"Ibrahim A, Ahmed M, Conway R, Carey JJ (2018) Risk of infection with methotrexate therapy in inflammatory diseases: a systematic review and meta-analysis. J Clin Med. 8(1):15","journal-title":"J Clin Med."},{"issue":"9","key":"13242_CR19","first-page":"e29518","volume":"14","author":"KM Hamed","year":"2022","unstructured":"Hamed KM, Dighriri IM, Baomar AF, Alharthy BT, Alenazi FE, Alali GH et al (2022) Overview of methotrexate toxicity: a comprehensive literature review. Cureus. 14(9):e29518","journal-title":"Cureus."},{"issue":"2","key":"13242_CR20","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/1744666X.2019.1705785","volume":"16","author":"YM Chiu","year":"2020","unstructured":"Chiu YM, Chen DY (2020) Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics. Expert Rev Clin Immunol. 16(2):207\u201328","journal-title":"Expert Rev Clin Immunol."}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13242-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13242-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13242-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T20:59:41Z","timestamp":1757278781000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13242-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["13242"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13242-6","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,24]]},"assertion":[{"value":"28 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors did not receive support from any organization for the submitted work. The authors have no relevant financial or non-financial interests to disclose.\u00a0The data supporting the findings of this study are available from the corresponding author upon reasonable request.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"531"}}